BioInvent International
11.12.2021 23:46:53 CET | ACCESS Newswire | Press release
- Objective response rate (ORR) 67% and disease control rate (DCR) 78% in Follicular lymphoma
- Complete responses lasting beyond 18, 24 and 36 months
LUND, SWEDEN / ACCESSWIRE / December 11, 2021 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announces updated positive interim top-line data from its novel anti-FcyRIIB antibody BI-1206 that show increased response levels and sustained complete responses. The data represent the status - to early November 2021 - of the company's Phase 1/2a clinical trial of BI-1206 in combination with rituximab (anti-CD20 monoclonal antibody) treating patients with indolent relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL). They are published today in a poster at the 63rd American Society of Hematology Annual Meeting and Exposition (ASH 2021).
The ASH 2021 poster shows that BI-1206 in combination with rituximab provided an objective response rate (ORR) of 54%, with three complete responses and four partial responses in 13 patients evaluated for therapeutic benefit for the three indications (Mantle cell lymphoma, Marginal zone lymphoma and Follicular lymphoma) enrolled in the clinical study. The treatment stabilized disease in one additional patient, giving a disease control rate of 62% (8 out of 13 patients).
When considered alone, the response rate for Follicular lymphoma is particularly impressive: of nine evaluable patients, three developed a CR, three developed a PR and one patient had SD at the cut-off date, giving a 67% ORR and 78% DCR. Previous rituximab treatments without BI-1206 had failed in these patients, prior to participation in the trial all patients had relapsed on earlier lines of rituximab-containing treatments.
All complete responses have been sustained for extended periods, with the longest complete response enduring beyond 36 months. In two additional patients, complete responses have lasted beyond 12 and 24 months after end of treatment.
"The current data are highly encouraging and already show the benefit of BI-1206 in rescuing rituximab treatment in advanced NHL. Without BI-1206, rituximab did not work well in these patients. Based on our deep understanding of the immune mechanisms at play, these data indicate that BI-1206 not only restores the anti-tumor response but does it safely and in a prolonged manner in many patients, notably in Follicular lymphoma. Adjusting the dosing regimen of BI-1206 could lead to yet further improvements. We look forward to discussing all these aspects with investors during our forthcoming KOL call on December 17," said Martin Welschof, PhD, CEO of BioInvent.
BioInvent will host a key opinion leader (KOL) webinar on BI-1206 featuring Michael Wang, M.D., from the MD Anderson Cancer Center, who will discuss the current NHL treatment landscape and unmet medical needs. Senior management will discuss the data presented at ASH 2021 and first data from the Phase 1/2a study of BI-1206 in combination with pembrolizumab for the treatment of solid tumors. The webinar will take place on Friday, December 17, 2021, at 1:00 pm ET/7:00 pm CET.
To register for the webinar, please click here .
BI-1206 is BioInvent's lead drug candidate and is currently being investigated in two Phase 1/2 trials. One is evaluating the BI-1206 combination with rituximab for the treatment of non-Hodgkin's lymphoma; and the other evaluates BI-1206 in combination with anti-PD1 therapy Keytruda® (pembrolizumab) in solid tumors. BI-1206 has also received approval to start clinical trials in China.
Since October 2020, BioInvent has a licensing agreement in place with CASI Pharmaceuticals for China, including Hong Kong, Macau, and Taiwan. Under the terms of the agreement, BioInvent and CASI will develop BI-1206 in both hematological and solid cancers, with CASI responsible for commercialization in China and associated markets.
ASH 2021 will take place on December 11-14, 2021, at the Georgia World Congress Center - Atlanta, GA, and virtually. BioInvent's poster is entitled "Phase 1/2a Clinical Trial of BI-1206, a Monoclonal Antibody to FcyRIIB, in Combination with Rituximab in Subjects with Indolent B-Cell Non-Hodgkin Lymphoma That Has Relapsed or is Refractory to Rituximab". The poster is presented today December 11 at 5.30 pm ET (11:30 pm CET).
About BioInvent
BioInvent International AB (Nasdaq Stockholm: BINV) is a clinical-stage biotech company that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently three drug candidates in four ongoing clinical programs in Phase 1/2 trials for the treatment of hematological cancer and solid tumors, respectively and a fifth program just initiating clinical development. The Company's validated, proprietary F.I.R.S.T™ technology platform simultaneously identifies both targets and the antibodies that bind to them, generating many promising new drug candidates to fuel the Company's own clinical development pipeline or for additional licensing and partnering.
The Company generates revenues from research collaborations and license agreements with multiple top-tier pharmaceutical companies, as well as from producing antibodies for third parties in the Company's fully integrated manufacturing unit. More information is available at www.bioinvent.com .
For further information, please contact:
Cecilia Hofvander
Senior Director Investor Relations
+46 (0)46 286 85 50
cecilia.hofvander@bioinvent.com
BioInvent International AB (publ)
Co. Reg. No. Org nr: 556537-7263
Visiting address: Ideongatan 1
Mailing address: 223 70 LUND
Phone: +46 (0)46 286 85 50
www.bioinvent.com
Disclaimer - BioInvent
The press release contains statements about the future, consisting of subjective assumptions and forecasts for future scenarios. Predictions for the future only apply as the date they are made and are, by their very nature, in the same way as research and development work in the biotech segment, associated with risk and uncertainty. With this in mind, the actual outcome may deviate significantly from the scenarios described in this press release.
This information is information that BioInvent International is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2021-12-11 23:30 CET.
Attachments
SOURCE: BioInvent International
View source version on accesswire.com:
https://www.accesswire.com/677141/BioInvents-Latest-NHL-Data-at-ASH-Show-Increased-and-Sustained-Responses-to-BI-1206-in-Relapsed-Patients
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
HrFlow.ai Secures 7 Million Dollars (Pre-Series A) to Become the Global Standard for Artificial Intelligence (AI) Applied to HR Data24.4.2026 01:40:00 CEST | Press release
PARIS, FR / ACCESS Newswire / April 23, 2026 / 1. Fundraising and Objectives HrFlow.ai, a pioneer in Artificial Intelligence applied to Human Resources data, announces its second fundraising round of $7M (pre-Series A) today. This financing brings the company's total capital raised to $10 million. This new capital injection is designed to accelerate the company's core mission: building the Data & AI infrastructure of the labor market. The round is led by 115K, La Banque Postale's venture capital fund, and EmergingTech Ventures (EmTech), alongside the company's existing investors including Xavier Niel (Free, Kima, Station F), Jean-Baptiste Rudelle (Criteo), Romain Niccoli (Pigment, Criteo), Franck Le Ouay (LIFEN, Criteo), Flavien Kulawik (KLB), Allen Penn (Uber), Dominique Vidal (Index Ventures), Thibaud Elzière (Hexa, Fotolia). Building on rigorous execution and proven capital efficiency since its first funding round of $2.3M in 2018, HrFlow.ai now generates a margin of approximately 2
Datavault AI Further Expands IP Portfolio with New Patent Issuance and Notices of Allowance22.4.2026 16:00:00 CEST | Press release
Builds on December 2025 Content Licensing Patents and Carbon Credit Tokenization Grant; Strengthens IP Moat Across Data Valuation, Virtual Funding, and Tokenized Tax Prep PHILADELPHIA, PA / ACCESS Newswire / April 22, 2026 / Datavault AI Inc. ("Datavault AI" or the "Company") (NASDAQ:DVLT), a leader in AI-driven data monetization, credentialing, digital engagement, and real-world asset ("RWA") tokenization technologies, today announced the issuance of U.S. Patent No. 12,596,819 and Notices of Allowance on two additional U.S. patent applications. This milestone builds directly on the Company's December 2025 issuance of two foundational patents for blockchain-driven content licensing and tokenized monetization - further expanding its robust intellectual property portfolio headlined by the industry-defining Carbon Credit Tokenization Patent. Key Highlights for Investors One newly issued patent and two Notices of Allowance extend protection across three high-value platforms: AI-validated d
Karbon-X Highlights SkyXero on Earth Day, Bringing Real-Time Climate Action to Travel22.4.2026 15:15:00 CEST | Press release
Company underscores leadership use and introduces matched contribution initiative to support verified climate projects. CALGARY, AB / ACCESS Newswire / April 22, 2026 / Karbon-X Corp. (OTCQX:KARX) ("Karbon-X" or the "Company"), a vertically integrated climate solutions provider operating across compliance and voluntary carbon markets, today marked Earth Day by highlighting SkyXero, its mobile application designed to help individuals understand and act on the emissions associated with their air travel. As global travel continues to increase, flight emissions remain one of the least visible and least understood components of individual environmental impact. SkyXero addresses this gap by enabling users to calculate emissions associated with any commercial flight and support verified climate projects such as reforestation, renewable energy, and carbon reduction initiatives. To reinforce its commitment to practical climate accountability, Karbon-X has applied SkyXero internally across its l
DOJO AI Raises $6M to Power Agentic Marketing Platform, Transforming Data Into Business Impact22.4.2026 14:00:00 CEST | Press release
Backed by Armilar and Heartfelt VC, the company serves over 100 customers across the U.S. and U.K., including CoinDesk, Morningstar, Broadvoice, PensionBee, CovertSwarm and Refine Labs LONDON, UK AND LISBON, PORTUGAL / ACCESS Newswire / April 22, 2026 / DOJO AI, the intelligent marketing system that brings a new class of integrated AI to marketing teams, today announced a $6 million seed round at a $30 million valuation. The round was led by Armilar, with participation from Heartfelt VC. The funding will support continued product development and accelerated expansion in the United States. DOJO AI introduces a new paradigm for marketing technology, powering what the industry is beginning to call agentic marketing: a system where AI agents don't just report on performance but take action on it. The platform watches paid and organic campaigns around the clock, audits SEO and Answer Engine Optimization visibility continuously, generates brand-aligned content, and feeds every outcome back i
GoodData Launches Agent Builder for Enterprise AI22.4.2026 12:00:00 CEST | Press release
Enterprises can now deploy governed analytics agents in minutes, with full control over configuration, context, and scale. SAN FRANCISCO, CA / ACCESS Newswire / April 22, 2026 / GoodData, the AI-powered analytics and decision intelligence platform, today announced the launch of Agent Builder, a new capability that expands its platform with a dedicated environment for building, configuring, and scaling AI agents across the enterprise. Agent Builder enables organizations to move beyond single-purpose AI assistants and instead deploy multiple, purpose-built analytics agents that can be precisely configured, governed, and scaled across customers, workspaces, and user groups. The launch addresses a growing enterprise challenge: while organizations are rapidly moving from experimentation to production with AI agents, consistent, secure, and scalable deployment across business units remains difficult without significant custom engineering. From Experimentation to Enterprise Scale While most a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom